184 related articles for article (PubMed ID: 34535560)
21. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
[TBL] [Abstract][Full Text] [Related]
22. Increasing CRISPR/Cas9-mediated homology-directed DNA repair by histone deacetylase inhibitors.
Li G; Zhang X; Wang H; Liu D; Li Z; Wu Z; Yang H
Int J Biochem Cell Biol; 2020 Aug; 125():105790. PubMed ID: 32534122
[TBL] [Abstract][Full Text] [Related]
23. Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
Waitkus MS; Yan H
Clin Cancer Res; 2021 Jan; 27(2):383-388. PubMed ID: 32883741
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
26. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
[TBL] [Abstract][Full Text] [Related]
27. Oncometabolites suppress DNA repair by disrupting local chromatin signalling.
Sulkowski PL; Oeck S; Dow J; Economos NG; Mirfakhraie L; Liu Y; Noronha K; Bao X; Li J; Shuch BM; King MC; Bindra RS; Glazer PM
Nature; 2020 Jun; 582(7813):586-591. PubMed ID: 32494005
[TBL] [Abstract][Full Text] [Related]
28. The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas.
Reiter-Brennan C; Semmler L; Klein A
Contemp Oncol (Pozn); 2018; 22(4):215-222. PubMed ID: 30783384
[TBL] [Abstract][Full Text] [Related]
29. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
[TBL] [Abstract][Full Text] [Related]
30. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Natsume A; Arakawa Y; Narita Y; Sugiyama K; Hata N; Muragaki Y; Shinojima N; Kumabe T; Saito R; Motomura K; Mineharu Y; Miyakita Y; Yamasaki F; Matsushita Y; Ichimura K; Ito K; Tachibana M; Kakurai Y; Okamoto N; Asahi T; Nishijima S; Yamaguchi T; Tsubouchi H; Nakamura H; Nishikawa R
Neuro Oncol; 2023 Feb; 25(2):326-336. PubMed ID: 35722822
[TBL] [Abstract][Full Text] [Related]
31. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
33. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
[TBL] [Abstract][Full Text] [Related]
34. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
[TBL] [Abstract][Full Text] [Related]
35. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
Liu Y; Gilbert MR; Kyprianou N; Rangnekar VM; Horbinski C
Acta Neuropathol; 2014 Nov; 128(5):723-32. PubMed ID: 25135281
[TBL] [Abstract][Full Text] [Related]
36. Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Leca J; Fortin J; Mak TW
Curr Opin Biotechnol; 2021 Apr; 68():181-185. PubMed ID: 33360716
[TBL] [Abstract][Full Text] [Related]
37. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
[TBL] [Abstract][Full Text] [Related]
38. PRMT1 driven PTX3 regulates ferritinophagy in glioma.
Lathoria K; Gowda P; Umdor SB; Patrick S; Suri V; Sen E
Autophagy; 2023 Jul; 19(7):1997-2014. PubMed ID: 36647288
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
40. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM
Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
